|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CRT leads to improvement in exercise capacity, cardiac function and mortality in selected CHF patients.
|
31353158 |
2020 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The beneficial effects of a cardiac resynchronization defibrillator (CRT-D) in patients with heart failure, low left ventricular ejection fraction (LVEF), and wide QRS have clearly been established.
|
31479745 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CRT is a therapeutic option for patients with heart failure, sinus rhythm, prolonged QRS complex duration and reduced ejection fraction.
|
29525386 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The efficacy of CRT-D vs. ICD only to reduce HF was similar in those with LVEF above and below 30% (HR 0.36, 95% CI 0.35-0.61, P < 0.001 vs. HR 0.46, 95% CI 0.35-0.61, P < 0.001; interaction P = 0.342).
|
30592353 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Most elderly patients with HF receiving CRT-D were overweight or obese.
|
31359595 |
2019 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A 53-year-old male with heart failure secondary to anterior wall myocardial infarction treated with cardiac resynchronization-defibrillator (CRT-D) device presented with ventricular arrhythmia: repetitive incessant slow ventricular tachycardias (VT) below the CRT-D detection zone, accelerated ventricular rhythm, and numerous premature ventricular ectopic beats (ExV), resulting in loss of biventricular pacing.
|
31241241 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to investigate the effects of remote monitoring on mortality in an optimally treated heart failure patient population undergoing cardiac resynchronization defibrillator therapy (CRT-D) implantation in a large-volume tertiary referral center.
|
31350836 |
2019 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To date, GLP-1 RA therapy may predict a reduction of AF events (HR 0.603, CI [0.411-0.884]), VT events (HR 0.964, CI [0.963-0.992]), and hospitalization for heart failure worsening (HR 0.119, CI [0.028-0.508]), and a higher CRT responders rate (HR 3.707, CI [1.226-14.570]).
|
30348145 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
A total of 563 consecutive patients with advanced heart failure and indication for CRT-D implantation were enrolled in two European tertiary centers.
|
29797055 |
2018 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Upon multivariate discriminant analysis, low patient activity, high nocturnal heart rate, and low CRT pacing (< 90%) proved to be independent predictors of true HF events (all p < 0.01).
|
28653309 |
2018 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
When further stratified according to aetiology, CRT-D was associated with a lower total mortality (HR 0.62), total mortality or HF hospitalization (HR 0.63), and total mortality or hospitalization for MACE (HR 0.59) (all P < 0.001) in patients with ischaemic cardiomyopathy (ICM).
|
29697764 |
2018 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
It remains unknown whether HF remission in DM patients with CRT-D translates into reduced mortality.
|
29625702 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
ENDURALIFE™-powered cardiac resynchronisation therapy defibrillator (CRT-D) devices were the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluation Programme, for the treatment of heart failure.
|
29086228 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In EchoCRT, HF patients with a narrow QRS complex and coexisting diabetes demonstrated a signal for less harm caused by CRT compared with patients without diabetes, which was driven by differences in hospitalizations owing to HF.
|
27862715 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Symptom severity assessed by NYHA functional class and QRS duration are essential criteria for selection of heart failure (HF) patients for CRT.
|
27338764 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical hypo-response was defined as HF event in the first year after CRT-D implantation.
|
28688704 |
2017 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Improvements in both survival and heart failure hospitalizations with CRT-D were greatest in patients with a QRSD ≥180 ms with or without LBBB, whereas patients with a QRSD 150 to 179 ms without LBBB had no improvement in survival with CRT-D, and those with a QRSD 150 to 179 ms and LBBB had only a modest improvement.
|
28427578 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ischemic CRT-D recipients respond as well as nonischemic recipients, using hospital admission for heart failure (HF) as a measure of response.
|
28846805 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both cardiac resynchronization therapy with a pacemaker (CRT-P) and with a biventricular implantable cardioverter-defibrillator (CRT-D) are electrical treatment modalities validated for the management of chronic heart failure.
|
27886920 |
2017 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
|
28003221 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
MS may be predictive for hospitalization for heart failure worsening (hazard ratio 0.327, 95% confidence interval 0.096-0.943, P = 0.044) in CRT-d patients.MS is a complex multifactorial disease that may affect the functionality of CRT-d leads, the CRT-d response, and clinical outcomes in failing heart patients.
|
28383431 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
A number of treatments were shown to be cost-effective, e.g., statin for secondary prevention of cardiovascular disease, aspirin for primary prevention of cardiovascular disease, DOAC for high-risk atrial fibrillation, beta blockers, ACE inhibitors, and ARB for heart failure, sildenafil and bosentan for pulmonary hypertension, CABG for multi-vessel coronary disease, ICD for ventricular tachycardia, and CRT for heart failure with low ejection fraction, while others were not cost-effective, e.g., epoprostenol for pulmonary hypertension and LVAD for end-stage heart failure.
|
29151496 |
2017 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
At 12 months, the selected miRNA profile was evaluated in plasma from responder (n = 55) and non-responder HF patients (n = 26) to CRT.
|
23736534 |
2013 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|